{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:51Z","timestamp":1791241671477,"version":"4.1.0"},"reference-count":98,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T00:00:00Z","timestamp":1338940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ovarian cancer is the leading cause of death among gynecological cancers. It exhibits great heterogeneity in tumor biology and treatment response. Germline mutations of DNA repair genes BRCA1\/2 are the fundamental defects in hereditary ovarian cancer that expresses a distinct phenotype of high response rates to platinum agents, improved disease-free intervals and survival rates, and high-grade serous histology. The term \u201cBRCAness\u201d describes the phenotypic traits that some sporadic ovarian tumors share with tumors in BRCA1\/2 germline mutation carriers and reflects similar causative molecular abnormalities. BRCA pathway studies and molecular profiling reveal BRCA-related defects in almost half of the cases of ovarian cancer. BRCA-like tumors are particularly sensitive to DNA-damaging agents (e.g., platinum agents) because of inadequate BRCA-mediated DNA repair mechanisms, such as nucleotide-excision repair and homologous recombination (HR). Additional inhibition of other DNA repair pathways leads to synthetic lethality in HR-deficient cells; this has been employed in the treatment of BRCA-like ovarian tumors with poly(ADP-ribose) polymerase inhibitors with promising results. This article presents a comprehensive review of the relevant literature on the role of BRCAness in ovarian cancer with respect to BRCA function, methods of BRCA epigenetic defect detection and molecular profiling, and the implications of BRCA dysfunction in the treatment of ovarian cancer.<\/jats:p>","DOI":"10.1634\/theoncologist.2012-0028","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T23:54:42Z","timestamp":1339026882000},"page":"956-962","source":"Crossref","is-referenced-by-count":83,"title":["BRCAness: Finding the Achilles Heel in Ovarian Cancer"],"prefix":"10.1093","volume":"17","author":[{"given":"Georgios","family":"Rigakos","sequence":"first","affiliation":[{"name":"Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Razis","sequence":"additional","affiliation":[{"name":"Third Department of Medical Oncology, Hygeia Hospital, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,6,6]]},"reference":[{"key":"2021122308133777600_B1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11912-001-0039-y","article-title":"Genetic factors in ovarian carcinoma","volume":"3","author":"Li","year":"2001","journal-title":"Curr Oncol Rep"},{"key":"2021122308133777600_B2","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"2021122308133777600_B3","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122308133777600_B4","first-page":"235","article-title":"Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1","volume":"4","author":"Aida","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2021122308133777600_B5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJM199611073351901","article-title":"Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1","volume":"335","author":"Rubin","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122308133777600_B6","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2009.25.1082","article-title":"Increased incidence of visceral metastases in Scottish patients with BRCA1\/2-defective ovarian cancer: An extension of the ovarian BRCAness phenotype","volume":"28","author":"Gourley","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2021122308133777600_B7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.1998.16.2.397","article-title":"Survival of BRCA1 breast and ovarian cancer patients: A population-based study from southern Sweden","volume":"16","author":"J\u00f3hannsson","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B8","first-page":"868","article-title":"Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group","volume":"59","author":"Pharoah","year":"1999","journal-title":"Cancer Res"},{"key":"2021122308133777600_B9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: The national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u201cBRCAness\u201d in sporadic cancers","volume":"4","author":"Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"2021122308133777600_B11","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: A case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B12","first-page":"3622","article-title":"Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer","volume":"56","author":"Foster","year":"1996","journal-title":"Cancer Res"},{"key":"2021122308133777600_B13","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: A population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res"},{"key":"2021122308133777600_B14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","article-title":"Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors","volume":"92","author":"Esteller","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"2021122308133777600_B15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jnci\/94.1.61","article-title":"Frequency of BRCA1 dysfunction in ovarian cancer","volume":"94","author":"Geisler","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122308133777600_B16","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/94.18.1396","article-title":"Inactivation of BRCA1 and BRCA2 in ovarian cancer","volume":"94","author":"Hilton","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122308133777600_B18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"2021122308133777600_B19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/path.1507","article-title":"Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene","volume":"202","author":"Wang","year":"2004","journal-title":"J Pathol"},{"key":"2021122308133777600_B20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ng0495-439","article-title":"Somatic mutations in the BRCA1 gene in sporadic ovarian tumours","volume":"9","author":"Merajver","year":"1995","journal-title":"Nat Genet"},{"key":"2021122308133777600_B21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1126\/science.7939630","article-title":"BRCA1 mutations in primary breast and ovarian carcinomas","volume":"266","author":"Futreal","year":"1994","journal-title":"Science"},{"key":"2021122308133777600_B22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/ng0696-238","article-title":"BRCA2 mutations in primary breast and ovarian cancers","volume":"13","author":"Lancaster","year":"1996","journal-title":"Nat Genet"},{"key":"2021122308133777600_B23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"2021122308133777600_B24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","article-title":"Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer","volume":"121","author":"Zhang","year":"2011","journal-title":"Gynecol Oncol"},{"key":"2021122308133777600_B25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.10.034","article-title":"BRCA1 promoter methylation predicts adverse ovarian cancer prognosis","volume":"101","author":"Chiang","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2021122308133777600_B26","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1038\/bjc.1996.234","article-title":"Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer","volume":"73","author":"Beckmann","year":"1996","journal-title":"Br J Cancer"},{"key":"2021122308133777600_B27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2005.08.026","article-title":"Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas","volume":"100","author":"Brown","year":"2006","journal-title":"Gynecol Oncol"},{"key":"2021122308133777600_B28","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0092-8674(03)00930-9","article-title":"EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer","volume":"115","author":"Hughes-Davies","year":"2003","journal-title":"Cell"},{"key":"2021122308133777600_B29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00438-011-0612-5","article-title":"EMSY overexpression disrupts the BRCA2\/RAD51 pathway in the DNA-damage response: Implications for chromosomal instability\/recombination syndromes as checkpoint diseases","volume":"285","author":"Cousineau","year":"2011","journal-title":"Mol Genet Genomics"},{"key":"2021122308133777600_B30","first-page":"290","article-title":"The Fanconi anemia\/BRCA signaling pathway: Disruption in cisplatin-sensitive ovarian cancers","volume":"2","author":"D'Andrea","year":"2003","journal-title":"Cell Cycle"},{"key":"2021122308133777600_B31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nm852","article-title":"Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors","volume":"9","author":"Taniguchi","year":"2003","journal-title":"Nat Med"},{"key":"2021122308133777600_B32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.cell.2006.11.042","article-title":"Essential role for nuclear PTEN in maintaining chromosomal integrity","volume":"128","author":"Shen","year":"2007","journal-title":"Cell"},{"key":"2021122308133777600_B33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1600-0412.2011.01121.x","article-title":"Identification of BRCA1-deficient ovarian cancers","volume":"90","author":"Skytte","year":"2011","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2021122308133777600_B34","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1093\/annonc\/mdq770","article-title":"Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: An NCIC CTG OV. 16 correlative study","volume":"22","author":"Weberpals","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122308133777600_B35","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/annonc\/mdq624","article-title":"An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients","volume":"22","author":"Vollebergh","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122308133777600_B36","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod Pathol"},{"key":"2021122308133777600_B37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122308133777600_B38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jnci\/94.13.990","article-title":"Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers","volume":"94","author":"Jazaeri","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122308133777600_B39","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2407-8-17","article-title":"Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities","volume":"8","author":"Press","year":"2008","journal-title":"BMC Cancer"},{"key":"2021122308133777600_B41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/jcp.52.5.372","article-title":"Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations","volume":"52","author":"Zweemer","year":"1999","journal-title":"J Clin Pathol"},{"key":"2021122308133777600_B42","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/carcin\/bgq069","article-title":"BRCA1 and BRCA2: Breast\/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair","volume":"31","author":"O'Donovan","year":"2010","journal-title":"Carcinogenesis"},{"key":"2021122308133777600_B43","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1093\/jnci\/djh312","article-title":"The role of BRCA1 in the cellular response to chemotherapy","volume":"96","author":"Kennedy","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122308133777600_B44","first-page":"4842","article-title":"Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation","volume":"61","author":"Moynahan","year":"2001","journal-title":"Cancer Res"},{"key":"2021122308133777600_B45","doi-asserted-by":"crossref","first-page":"23899","DOI":"10.1074\/jbc.C000276200","article-title":"The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin","volume":"275","author":"Bhattacharyya","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122308133777600_B46","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/cncr.11310","article-title":"Improved survival in women with BRCA-associated ovarian carcinoma","volume":"97","author":"Cass","year":"2003","journal-title":"Cancer"},{"key":"2021122308133777600_B47","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"2021122308133777600_B48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/gcc.10105","article-title":"Subcellular localization of the BRCA1 gene product in mitotic cells","volume":"35","author":"Lotti","year":"2002","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122308133777600_B49","first-page":"7713","article-title":"Identification of a gamma-tubulin-binding domain in BRCA1","volume":"61","author":"Hsu","year":"2001","journal-title":"Cancer Res"},{"key":"2021122308133777600_B50","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1038\/sj.onc.1204812","article-title":"Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway","volume":"20","author":"Lafarge","year":"2001","journal-title":"Oncogene"},{"key":"2021122308133777600_B51","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0092-8674(00)80769-2","article-title":"Induction of GADD45 and JNK\/SAPK-dependent apoptosis following inducible expression of BRCA1","volume":"97","author":"Harkin","year":"1999","journal-title":"Cell"},{"key":"2021122308133777600_B52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1349-7006.2006.00265.x","article-title":"Predictive factors for response to docetaxel in human breast cancers","volume":"97","author":"Noguchi","year":"2006","journal-title":"Cancer Sci"},{"key":"2021122308133777600_B53","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/sj.bjc.6600859","article-title":"BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells","volume":"88","author":"Tassone","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122308133777600_B54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO;2-O","article-title":"Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer","volume":"95","author":"Egawa","year":"2001","journal-title":"Int J Cancer"},{"key":"2021122308133777600_B55","first-page":"407","article-title":"Overexpression of Akt\/AKT can modulate chemotherapy-induced apoptosis","volume":"20","author":"Page","year":"2000","journal-title":"Anticancer Res"},{"key":"2021122308133777600_B56","first-page":"845","article-title":"Dominant-negative activity of a Brca1 truncation mutant: Effects on proliferation, tumorigenicity in vivo, and chemosensitivity in a mouse ovarian cancer cell line","volume":"20","author":"Sylvain","year":"2002","journal-title":"Int J Oncol"},{"key":"2021122308133777600_B57","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/sj.onc.1206319","article-title":"Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1","volume":"22","author":"Zhou","year":"2003","journal-title":"Oncogene"},{"key":"2021122308133777600_B58","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-07-1083","article-title":"BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy","volume":"13","author":"Quinn","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122308133777600_B59","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","article-title":"Integrating genetic approaches into the discovery of anticancer drugs","volume":"278","author":"Hartwell","year":"1997","journal-title":"Science"},{"key":"2021122308133777600_B60","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMe0903044","article-title":"Synthetic lethality\u2014A new direction in cancer-drug development","volume":"361","author":"Iglehart","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122308133777600_B61","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/genetics\/31.3.269","article-title":"Genetics of natural populations: Recombination and variability in populations of Drosophila pseudoobscura","volume":"31","author":"Dobzhansky","year":"1946","journal-title":"Genetics"},{"key":"2021122308133777600_B62","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/annonc\/mdq322","article-title":"A review of PARP inhibitors: From bench to bedside","volume":"22","author":"Underhill","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122308133777600_B63","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"2021122308133777600_B64","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"2021122308133777600_B65","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"2021122308133777600_B66","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","article-title":"Poly(ADP)-ribose polymerase inhibition: Frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval","volume":"28","author":"Fong","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B67","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"4-[3-(4-Cyclopropanecarbonylpiperazine-1- carbonyl)-4-f luorobenzyl]-2H-phthalazin-1- one: A novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J Med Chem"},{"key":"2021122308133777600_B68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial","volume":"376","author":"Tutt","year":"2010","journal-title":"Lancet"},{"key":"2021122308133777600_B69","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"2021122308133777600_B70","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res"},{"key":"2021122308133777600_B71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308133777600_B72","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/jco.2011.29.15_suppl.1007","article-title":"A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine\/carboplatin (G\/C) in metastatic triple-negative breast cancer (TNBC)","volume":"29","author":"O'Shaughnessy","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/1078-0432.CCR-11-1973","article-title":"Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor","volume":"18","author":"Liu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122308133777600_B74","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-11-2890","article-title":"Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro","volume":"18","author":"Patel","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2021122308133777600_B75","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B76","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(11)70236-4","article-title":"PARP inhibitors in cancer: Moving beyond BRCA","volume":"12","author":"Telli","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308133777600_B77","first-page":"1","article-title":"PARP inhibition in epithelial ovarian cancer: High hopes undergo a reality check","volume":"26","author":"Zorn","year":"2012","journal-title":"Oncology"},{"key":"2021122308133777600_B78","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1200\/jco.2010.28.15_suppl.5041","article-title":"Preliminary experience with the use of chemotherapy (CT) following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi), in patients with BRCA1\/2-deficient ovarian cancer (BDOC)","volume":"28","author":"Ang","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B79","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"2021122308133777600_B80","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/0008-5472.CAN-08-0088","article-title":"Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance","volume":"68","author":"Swisher","year":"2008","journal-title":"Cancer Res"},{"key":"2021122308133777600_B81","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2010.34.2980","article-title":"Secondary somatic mutations restoring BRCA1\/2 predict chemotherapy resistance in hereditary ovarian carcinomas","volume":"29","author":"Norquist","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B82","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"2021122308133777600_B83","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3322\/caac.20095","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic","volume":"61","author":"Yap","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"42","key":"2021122308133777600_B84","first-page":"140","article-title":"Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: Teaching old dogs new tricks?","volume":"8","author":"Gabra","year":"2009","journal-title":"Discov Med"},{"key":"2021122308133777600_B85","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.dnarep.2008.08.014","article-title":"A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity","volume":"7","author":"Lord","year":"2008","journal-title":"DNA Repair (Amst)"},{"key":"2021122308133777600_B86","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/emboj.2008.61","article-title":"A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor","volume":"27","author":"Turner","year":"2008","journal-title":"EMBO J"},{"key":"2021122308133777600_B87","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1200\/JCO.2010.30.1010","article-title":"BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors","volume":"28","author":"Veeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308133777600_B88","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","article-title":"Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","volume":"16","author":"Mukhopadhyay","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308133777600_B89","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1172\/JCI31245","article-title":"Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated","volume":"117","author":"Kennedy","year":"2007","journal-title":"J Clin Invest"},{"key":"2021122308133777600_B90","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-09-0872","article-title":"ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors","volume":"9","author":"Williamson","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2021122308133777600_B91","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/emmm.200900041","article-title":"Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors","volume":"1","author":"Mendes-Pereira","year":"2009","journal-title":"EMBO Mol Med"},{"key":"2021122308133777600_B92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2005.01.009","article-title":"Lack of PTEN sequesters CHK1 and initiates genetic instability","volume":"7","author":"Puc","year":"2005","journal-title":"Cancer Cell"},{"key":"2021122308133777600_B93","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ctrv.2009.11.006","article-title":"Forkhead box M1 transcription factor: A novel target for cancer therapy","volume":"36","author":"Wang","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"2021122308133777600_B94","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1128\/MCB.01068-06","article-title":"Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes","volume":"27","author":"Tan","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2021122308133777600_B95","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1158\/0008-5472.CAN-10-2352","article-title":"Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment","volume":"70","author":"Chan","year":"2010","journal-title":"Cancer Res"},{"key":"2021122308133777600_B96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/0008-5472.CAN-07-5472","article-title":"Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance","volume":"68","author":"Chan","year":"2008","journal-title":"Cancer Res"},{"key":"2021122308133777600_B97","doi-asserted-by":"crossref","first-page":"11597","DOI":"10.1158\/0008-5472.CAN-05-2119","article-title":"Hypoxia-induced down-regulation of BRCA1 expression by E2Fs","volume":"65","author":"Bindra","year":"2005","journal-title":"Cancer Res"},{"key":"2021122308133777600_B98","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2005.06.025","article-title":"Hypoxia down-regulates DNA double-strand break repair gene expression in prostate cancer cells","volume":"76","author":"Meng","year":"2005","journal-title":"Radiother Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2012-0028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0028","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/7\/956\/41858461\/oncolo_17_7_956.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/7\/956\/41858461\/oncolo_17_7_956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T15:19:56Z","timestamp":1640272796000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/7\/956\/6403273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,6]]},"references-count":98,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2012,6,6]]},"published-print":{"date-parts":[[2012,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0028","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,7,1]]},"published":{"date-parts":[[2012,6,6]]}}}